Form 4: Teva CFO Sells Shares Under 10b5-1 Plan

Teva Pharmaceutical Industries Ltd. CFO Eliyahu Sharon Kalif sold a significant number of ordinary shares under a pre-arranged trading plan.

Summary

• Eliyahu Sharon Kalif, EVP and Chief Financial Officer of Teva Pharmaceutical Industries Ltd., reported a transaction involving the sale of ordinary shares.
• The sale occurred on May 14, 2026, and involved 153,251 ordinary shares.
• These shares were sold at a weighted average price of $35.6107, with individual transactions ranging from $35.59 to $35.80.
• The transaction was executed under a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025.
• Following the reported transaction, Kalif beneficially owns 172,184 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sale was conducted under a pre-established 10b5-1 plan, indicating a planned divestment rather than a reaction to new information.

Negatives

• The CFO sold a substantial number of shares, which could be perceived negatively by the market, although it was executed under a pre-planned trading strategy.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a past transaction.

Industry Context

StockSavvy.ai notes that insider sales, even under a 10b5-1 plan, can sometimes lead to short-term market scrutiny. However, the existence of the plan itself is designed to mitigate concerns about trading on material non-public information.

Stakeholder Impact

• Shareholders: May interpret the CFO's sale as a signal, though the 10b5-1 plan provides a defense against insider trading allegations.
• Employees: May observe the sale as part of normal executive compensation and diversification strategies.
• Creditors: Unlikely to be directly impacted by this specific transaction.

Key Dates

Keywords

Teva Pharmaceutical Industries, Form 4, insider trading, Rule 10b5-1, stock sale, CFO, Eliyahu Sharon Kalif, beneficial ownership